Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 217869, held by Glenmark Pharms Ltd. Topiramate.
As of Nov 15, 2026, ANDA 217869 (Topiramate), held by Glenmark Pharms Ltd, was first approved by FDA on Jul 16, 2024, with 1 approved supplement and 0 published complete response letters.
First approved: Jul 16, 2024
Review: Standard
Supplements approved: 1
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Topiramate capsules are indicated for:
Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older
Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters